EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives

Yu Guo iD, Keqiang Lu, Wenmiao Luo iD, Min Wei, Fangbao Li, Maoxiang Li, Juanjuan Peng, Mingfei Yang iD, Lingzhi Zhao, Hengzhu Zhang iD

WIREs Nanomedicine and Nanobiotechnology · 2026-07 · 18 (4)

DOI: 10.1002/wnan.70071 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 28.07.2026. Verfasst von Yu Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Glioblastoma, Nanomedicine, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Jiangsu Commission of Health, Natural Science Foundation of Yangzhou Municipality, Natural Science Foundation of Qinghai Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal‐oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli‐responsive nano‐systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNanomedicineBrain NeoplasmsHumansAnimalsBlood-Brain BarrierDrug Delivery SystemsAntineoplastic Agents

Stichwörter der Autor:innen

blood–brain barrierglioblastomananomedicinestimuli‐responsive nanosystemstargeted drug delivery

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Neurosurgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, People's Republic of China.
  • Department of Neurosurgery, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, People's Republic of China.
  • Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • State Key Laboratory of Natural Medicine, the School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, People's Republic of China.
  • Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
  • Department of Neurosurgery, Qinghai Provincial People's Hospital, Xining, Qinghai, People's Republic of China.

ORCID-Profile: Yu Guo, Wenmiao Luo, Mingfei Yang, Hengzhu Zhang

Förderung

  • Jiangsu Commission of Health
  • Natural Science Foundation of Yangzhou Municipality
  • Natural Science Foundation of Qinghai Province

Zitieren

APA

Guo, Y., Lu, K., Luo, W., Wei, M., Li, F., Li, M., Peng, J., Yang, M., Zhao, L., & Zhang, H. (2026). Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives. WIREs Nanomedicine and Nanobiotechnology, 18(4). https://doi.org/10.1002/wnan.70071

Vancouver

Guo Y, Lu K, Luo W, Wei M, Li F, Li M, et al. Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives. WIREs Nanomedicine and Nanobiotechnology. 2026;18(4). doi:10.1002/wnan.70071

BibTeX
@article{Guo2026,
  author = {Guo, Yu and Lu, Keqiang and Luo, Wenmiao and Wei, Min and Li, Fangbao and Li, Maoxiang and Peng, Juanjuan and Yang, Mingfei and Zhao, Lingzhi and Zhang, Hengzhu},
  title = {Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives},
  journal = {WIREs Nanomedicine and Nanobiotechnology},
  year = {2026},
  volume = {18},
  number = {4},
  doi = {10.1002/wnan.70071}
}
Kostenlos starten →